AdvaMed makes use of Senate debate with medtech survey
This article was originally published in Clinica
Executive Summary
European regulators received higher marks than the FDA in a new survey released last week by AdvaMed. Three out of four device companies polled claimed they can get their technologies to market faster in Europe than in the US, while only 5% reported the opposite experience. The remaining 19% said there was no difference in product development times between the two jurisdictions.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.